标题
Emerging gliptins for type 2 diabetes
作者
关键词
-
出版物
EXPERT OPINION ON EMERGING DRUGS
Volume 18, Issue 2, Pages 245-258
出版商
Informa Healthcare
发表日期
2013-06-03
DOI
10.1517/14728214.2013.807796
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
- (2013) Wendy L. Bennett et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
- (2013) E. J. Rhee et al. DIABETES OBESITY & METABOLISM
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- (2013) Y. G. Kim et al. DIABETOLOGIA
- Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study
- (2013) D. T. Eurich et al. BMJ-British Medical Journal
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Steven G. Chrysant et al. AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
- (2012) Haesuk Park et al. ANNALS OF PHARMACOTHERAPY
- Recent advances in incretin-based therapies
- (2012) David Russell-Jones et al. CLINICAL ENDOCRINOLOGY
- Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
- (2012) Anthony H. Barnett et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Diabetes in Older Adults
- (2012) M. S. Kirkman et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial
- (2012) T. Eto et al. DIABETES OBESITY & METABOLISM
- Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study
- (2012) E. S. Hong et al. DIABETES OBESITY & METABOLISM
- Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
- (2012) W. Kothny et al. DIABETES OBESITY & METABOLISM
- Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
- (2012) K. Gooßen et al. DIABETES OBESITY & METABOLISM
- Effect of Sitagliptin on Post-Prandial Glucagon and GLP-1 Levels in Patients With Type 1 Diabetes: Investigator-Initiated, Double-Blind, Randomized, Placebo-Controlled Trial
- (2012) Satish Garg et al. Endocrine Practice
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations
- (2012) Sayaka Fukuda-Tsuru et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin
- (2012) James Thrasher et al. EXPERT OPINION ON PHARMACOTHERAPY
- What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes
- (2012) Christopher Ll. Morgan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes
- (2012) Johan Farngren et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies
- (2012) Nancy J. Brown Journal of the American Society of Hypertension
- A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
- (2012) Shinji Furuta et al. XENOBIOTICA
- The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
- (2011) Benjamin M. Scirica et al. AMERICAN HEART JOURNAL
- Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
- (2011) Kathleen R. Richard et al. CLINICAL THERAPEUTICS
- An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development
- (2011) Christopher Viereck et al. Contemporary Clinical Trials
- Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
- (2011) Nir Barzilai et al. CURRENT MEDICAL RESEARCH AND OPINION
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual -Cell Function
- (2011) U. Kielgast et al. DIABETES CARE
- Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
- (2011) M. J. Willemen et al. DIABETES CARE
- Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence
- (2011) R. E. van Genugten et al. DIABETES OBESITY & METABOLISM
- Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
- (2011) Roberta Baetta et al. DRUGS
- Liraglutide as additional treatment for type 1 diabetes
- (2011) Ajay Varanasi et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A review of gliptins in 2011
- (2011) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Patient perspectives on once-weekly medications for diabetes
- (2010) W. H. Polonsky et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis
- (2010) Hans D. Theiss et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
- (2010) S. S. Engel et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
- (2010) Jack L. Leahy et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
- (2010) Jaime A. Davidson MAYO CLINIC PROCEEDINGS
- Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration
- (2010) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomics, Type 2 Diabetes, and Obesity
- (2010) Mark I. McCarthy NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
- (2009) Kyoung Soo Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Exenatide Alone and in Combination With Daclizumab on -Cell Function in Long-Standing Type 1 Diabetes
- (2009) K. I. Rother et al. DIABETES CARE
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- The effects of glucagon-like peptide-1 on the beta cell
- (2009) T. Vilsbøll DIABETES OBESITY & METABOLISM
- DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue
- (2009) K. Kos et al. DIABETES OBESITY & METABOLISM
- Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
- (2009) K. Aaboe et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
- (2009) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
- (2009) Jay S. Skyler et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Economic Costs of Diabetes in the U.S. in 2007
- (2008) DIABETES CARE
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide and Rare Adverse Events
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More